Transgene FY26 H1 net loss narrows 18.79% to €15.67 million
Bitget2026/09/24 15:45- Transgene posted a net loss of EUR 15.67 million for H1 2026, narrowing from EUR 19.3 million a year earlier.
- Operating loss narrowed to EUR 16.74 million, while operating income fell 34.64% to EUR 2.99 million.
- Cash and equivalents totaled EUR 92.8 million at June 30, down from EUR 111.9 million at Dec. 31.
- Cash burn rose to EUR 20.3 million, and financial visibility was reiterated through early 2028 under current plans.
- TG4050 Phase 2 recruitment finished, TG4070 Phase 1 started, and TG-MVA advanced toward clinical development on positive preclinical data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns
Due to increased market concerns over AI-related financing and potential large-scale acquisitions, SoftBank Group's credit risk indicator—the credit default swap (CDS)—has risen to its highest level in nearly four years.

Microsoft (MSFT.US) faces a "higher bar" after its rebound! Morgan Stanley remains bullish: Azure growth and Copilot commercialization are key drivers, target price set at $600
Morgan Stanley stated that Microsoft's stock price has recently rebounded, so the tech giant will face a "higher hurdle" if it wants to maintain its upward momentum.

Report: OpenAI plans to accelerate fundraising before Anthropic goes public
OpenAI is racing against time—in order to secure funding ahead of rival Anthropic’s IPO, the company has significantly compressed its fundraising timeline, aiming to complete approximately $30 billion in private financing, which could push its valuation past $1.4 trillion upon completion. Major investors such as SoftBank and MGX are already engaged in discussions. Both AI giants are targeting trillion-dollar valuations, and their largely overlapping investor bases are being forced to make simultaneous bets on both ventures within just a few days.

